Oct 29 2020, 11:06 AM, updated 6y ago
Israel to begin clinical trials of Covid-19 vaccine
Testing of BriLife vaccine developed at Israel Institute for Biological Research begins at Hadassah and Sheba medical centers on healthy volunteers.
26 Oct 2020 SoS
Israel begins mass-producing coronavirus vaccines ahead of human trials
Aiming for regulatory approval by July, Institute for Biological Research to develop 15 million doses for Israelis, Palestinians and other possible buyers
26 Oct 2020 SoS
QUOTE
...The Israel Defense Ministry on Sunday announced that the first human trials of its coronavirus vaccine will begin next Sunday, November 1, and continue through next spring before it can receive approval for full use.
The Israel Institute for Biological Research (IIRB) will begin the first phase of the testing process with two initial participants, increasing to 80 over the month of November. If they respond well to the vaccine and develop antibodies against the virus, the testing will expand to 960 people beginning in December.
...The vaccine is named Brilife, a portmanteau of the Hebrew word for health — bri’ut — and life. The name also contains the abbreviation for Israel, IL, as well as the letters that make up the acronym of the laboratory, IIRB.
...The first stage of testing will use healthy participants, aged 18 to 55; the second stage will use healthy participants older than 18; and the third stage will have no limitation on the age or medical condition of the participants.
In the second stage of testing, the Defense Ministry said, scientists aim to “complete vaccine safety precautions, determine effective dosage, and further determine the vaccine’s effectiveness.”
The third and final stage will ensure its efficacy throughout the population.
The Institute for Biological Research, a generally shadowy organization that operates under the auspices of the Defense Ministry on issues related to chemical and biological warfare, said it used state-of-the-art techniques to create its vaccine.
The state-run laboratory based its vaccine on an existing virus, Indiana vesiculovirus, also known as VSV. The institute attached the spikes present on the novel coronavirus onto VSV, giving these portions of the virus a way to attach to the human body, which in turn allows the body to safely produce antibodies against it without being infected with the disease itself.
...“Our final goal is 15 million doses for the residents of the State of Israel and for our close neighbors,” said Prof. Shmuel Shapira, director of the IIBR.
Quote
0.0215sec
0.89
5 queries
GZIP Disabled